Business Context and Reporting Period
Company: Ispire Technology Inc. (ISPR)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2026
Business Overview: Ispire designs, manufactures, and distributes branded and non-branded vaping hardware for nicotine and cannabis markets. The company operates under the "Aspire" brand for nicotine products and "Ispire" for cannabis hardware. It maintains a manufacturing facility in Malaysia and relies heavily on Shenzhen Yi Jia, a related party owned 95% by CEO Tuanfang Liu, for product supply. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 |
|---|---|---|
| Revenue | $96.0 million | $127.5 million |
| Gross Profit | $12.3 million | $22.6 million |
| Gross Margin | 12.8% | 17.8% |
| Net Loss | $(33.2) million | $(39.2) million |
| Loss Per Share (Basic/Diluted) | $(0.58) | $(0.69) |
| Operating Cash Flow | $(0.6) million | $(7.4) million |
| Cash and Restricted Cash | $19.4 million | $24.4 million |
| Total Assets | $64.3 million | $102.2 million |
| Total Liabilities | $93.5 million | $101.6 million |
| Stockholders' Equity (Deficit) | $(29.2) million | $0.6 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 24.7% to $96.0 million. This was driven by a $17.4 million drop in North American sales due to stricter payment terms and a $12.7 million decline in European sales attributed to regulatory uncertainty regarding disposable bans.
- Margin Compression: Gross margin contracted from 17.8% to 12.8%. Contributing factors included competitive pricing pressures, a shift in revenue mix away from higher-margin cannabis products (down from 29.0% to 16.6% of total revenue), and a significant increase in inventory write-downs to $2.8 million from $0.8 million.
- Loss Reduction: Net loss improved by $6.0 million (15.4%) primarily due to a 25.8% reduction in operating expenses, driven by headcount reductions and cost optimization in North America.
- Working Capital: Working capital increased to $0.8 million from $0.4 million, though total current assets declined 37.7% to $45.4 million.
- Related Party Balances: Accounts payable to related party Shenzhen Yi Jia decreased to $29.3 million from $52.4 million, while a non-current amount due to the related party increased to $47.0 million from $25.0 million.
Guidance, Outlook, Risks, and Contingencies
- Regulatory Environment: The company is not marketing nicotine products in the U.S. pending FDA Premarket Tobacco Product Application (PMTA) approvals. It is pursuing PMTAs for devices equipped with age-gating technology developed by its joint venture, IKE Tech LLC. The FDA recently authorized flavored ENDS products with age-gating, providing a potential pathway for Ispire.
- Manufacturing: Ispire Malaysia received full licensure in March 2026 to manufacture nicotine vapor products. The company is transitioning from reliance on Shenzhen Yi Jia to its own assembly operations, though it faces risks regarding operational efficiency and cost management.
- Joint Ventures: Ispire holds a 40% interest in IKE Tech LLC (age-gating technology) and a 49% interest in Jin Wu Health Limited (nicotine pouches). Both are pre-revenue. The company has a committed investment of $9 million into IKE, with $3.5 million recorded as payable.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of June 30, 2026, due to a material weakness in IT general controls (cybersecurity governance and logical access). Previous weaknesses regarding inventory and credit loss estimates were remediated.
- Related Party Conflict: CEO Tuanfang Liu and his wife own 62.1% of the company and control the majority supplier, Shenzhen Yi Jia, creating significant conflict of interest risks regarding pricing and supply terms.
- Liquidity: The company has historically reported negative cash flows. While it believes current cash and operating cash flows are sufficient for the next 12 months, it may require additional financing if growth accelerates or adverse conditions occur.
Investor Verification Checklist
- Related Party Transactions: Verify the pricing fairness of purchases from Shenzhen Yi Jia (91% of total purchases) and the terms of the $47 million non-current debt owed to the related party.
- Inventory Valuation: Assess the adequacy of the $2.8 million inventory write-down and the risk of further obsolescence given the decline in sales and regulatory bans on disposables in the UK.
- Accounts Receivable Quality: Review the $26.1 million allowance for credit losses (up from $18.0 million) and the collectability of receivables from cannabis operators facing economic headwinds.
- FDA PMTA Status: Monitor the progress of the IKE Tech LLC age-gating PMTA and Ispire's own PMTA submissions, as U.S. market access is contingent on these approvals.
- Internal Control Remediation: Track the implementation of the remediation plan for the material weakness in IT general controls to ensure future financial reporting reliability.
- Joint Venture Capital Calls: Confirm the company's ability to fund the remaining $5.5 million commitment to IKE Tech LLC without diluting existing shareholders or incurring excessive debt.